Web Exclusives

Remote working in the life sciences industry

How to ensure post-lockdown success

29th July 2020

Virtual care here to stay

Ninety percent of patients surveyed globally reported that quality of care was as good or better than prior in-person care

21st July 2020

Never the same again

Gary Hughes explains why we’re witnessing a complete transformation of the clinical trial process in the wake of COVID-19

14th July 2020

Dealing with disruption

Why cancer care technology must support both clinicians and patients

14th July 2020

A strong foundation

The value of pre-existing collaboration in COVID-19 clinical trials

8th July 2020

Patient Partnership Index: ‘We Can’t Do It Alone’

David Peacock, MSD UK’s managing director, shares his thoughts on why companies should enter the Patient Partnership Index

2nd July 2020

Battling the cytokine storm

A look at some of pharma's approaches to addressing the potentially deadly hyperinflammation seen in some patients with COVID-19

25th June 2020

The need for digitalisation of pharma R&D

If COVID-19 has taught us anything, it’s that we need speed and accuracy now, and digitalisation could help

24th June 2020

US clinical R&D hits new highs

COVID-19 has disrupted clinical trial activity but has simultaneously unleashed a flurry of new innovations that will continue to drive growth in the field, says Murray Aitken

15th June 2020

A matter of life and death

Healthcare staffing in a pandemic: the role of big data, analytics, cloud computing and visualisation

11th June 2020

Building a domestic manufacturing capacity

The importance of the UK building a domestic pharmaceutical and vaccine manufacturing sector, both in the context of COVID-19 and exiting the EU

9th June 2020

Engaging neurodivergent talent for pharma roles

Neurodivergent individuals are systematically overlooked in recruitment processes but are a talent pool that could be highly valuable to the pharma sector, says Marita Hazeldene

26th May 2020